Product Code: ETC12320133 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Hormone Refractory Prostate Cancer Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Hormone Refractory Prostate Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 China Hormone Refractory Prostate Cancer Market - Industry Life Cycle |
3.4 China Hormone Refractory Prostate Cancer Market - Porter's Five Forces |
3.5 China Hormone Refractory Prostate Cancer Market Revenues & Volume Share, By Cancer Stage, 2021 & 2031F |
3.6 China Hormone Refractory Prostate Cancer Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 China Hormone Refractory Prostate Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 China Hormone Refractory Prostate Cancer Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 China Hormone Refractory Prostate Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of prostate cancer in China |
4.2.2 Advancements in medical research leading to the development of new treatment options |
4.2.3 Growing awareness and adoption of targeted therapies for hormone refractory prostate cancer |
4.3 Market Restraints |
4.3.1 High cost associated with advanced treatment options |
4.3.2 Limited access to specialized healthcare facilities in certain regions of China |
4.3.3 Stringent regulatory requirements for approval of new therapies |
5 China Hormone Refractory Prostate Cancer Market Trends |
6 China Hormone Refractory Prostate Cancer Market, By Types |
6.1 China Hormone Refractory Prostate Cancer Market, By Cancer Stage |
6.1.1 Overview and Analysis |
6.1.2 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Cancer Stage, 2021 - 2031F |
6.1.3 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Castration-resistant Prostate Cancer, 2021 - 2031F |
6.1.4 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Metastatic Hormone-refractory Cancer, 2021 - 2031F |
6.1.5 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Non-metastatic Hormone-refractory Cancer, 2021 - 2031F |
6.1.6 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Recurrent Prostate Cancer, 2021 - 2031F |
6.2 China Hormone Refractory Prostate Cancer Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.3 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.4 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Androgen Receptor Inhibitors, 2021 - 2031F |
6.2.5 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Radioisotope Therapy, 2021 - 2031F |
6.3 China Hormone Refractory Prostate Cancer Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Men Aged 50+, 2021 - 2031F |
6.3.3 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.3.4 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Urology Clinics, 2021 - 2031F |
6.3.5 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Cancer Research Institutes, 2021 - 2031F |
6.4 China Hormone Refractory Prostate Cancer Market, By Application |
6.4.1 Overview and Analysis |
6.4.2 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Late-stage Cancer Treatment, 2021 - 2031F |
6.4.3 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Advanced Prostate Cancer Care, 2021 - 2031F |
6.4.4 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Localized Prostate Cancer, 2021 - 2031F |
6.4.5 China Hormone Refractory Prostate Cancer Market Revenues & Volume, By Precision Oncology, 2021 - 2031F |
7 China Hormone Refractory Prostate Cancer Market Import-Export Trade Statistics |
7.1 China Hormone Refractory Prostate Cancer Market Export to Major Countries |
7.2 China Hormone Refractory Prostate Cancer Market Imports from Major Countries |
8 China Hormone Refractory Prostate Cancer Market Key Performance Indicators |
8.1 Patient survival rate post-treatment |
8.2 Adoption rate of new targeted therapies |
8.3 Percentage of healthcare providers offering specialized care for hormone refractory prostate cancer |
8.4 Research and development investment in innovative treatment options |
8.5 Patient satisfaction and quality of life post-treatment |
9 China Hormone Refractory Prostate Cancer Market - Opportunity Assessment |
9.1 China Hormone Refractory Prostate Cancer Market Opportunity Assessment, By Cancer Stage, 2021 & 2031F |
9.2 China Hormone Refractory Prostate Cancer Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 China Hormone Refractory Prostate Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 China Hormone Refractory Prostate Cancer Market Opportunity Assessment, By Application, 2021 & 2031F |
10 China Hormone Refractory Prostate Cancer Market - Competitive Landscape |
10.1 China Hormone Refractory Prostate Cancer Market Revenue Share, By Companies, 2024 |
10.2 China Hormone Refractory Prostate Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |